Sign In
Buy TGTX
$55.01
-2.11 (-3.69%)
At Close: Jul 13, 2026
2 Fast-Growing Pharmaceutical Stocks to Buy Now
08:05pm, Wednesday, 08'th Jul 2026
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
10:01am, Tuesday, 07'th Jul 2026
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
07:30am, Monday, 06'th Jul 2026
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to dise
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
09:55am, Friday, 03'rd Jul 2026
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
03:29pm, Thursday, 18'th Jun 2026
TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing
08:00am, Wednesday, 17'th Jun 2026
TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
06:16am, Thursday, 11'th Jun 2026
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
10:21am, Wednesday, 10'th Jun 2026
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:12pm, Tuesday, 09'th Jun 2026
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed
Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi
12:01pm, Thursday, 04'th Jun 2026
TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
09:00am, Thursday, 04'th Jun 2026
TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event for TG's most important clinical development program. SC Briumvi's bioavailability, safety, and tolerabilit
TG Therapeutics Stock Surges After Drug Trial Update
03:19pm, Wednesday, 03'rd Jun 2026
Shares of TG Therapeutics Inc (NASDAQ:TGTX) are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Her
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
07:30am, Wednesday, 03'rd Jun 2026
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026
